Humanitas Proton Therapy (HU-PRO) Registry

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

HU-PRO is an observational registry run by Istituto Clinico Humanitas that gathers clinical, treatment, toxicity, and outcome data on adult patients treated with proton therapy. Enrollment targets patients eligible for proton therapy under Italian national guidelines, including selected indications and re-irradiation cases. The registry records performance status, treatment parameters, side effects, and disease control during follow-up to build real-world evidence. Collected data are intended to support broader development, optimize patient selection, and improve treatment safety and effectiveness.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Solid tumors candidate to proton therapy, in particular, according to Italian regolamentations
* Written informed consent for HU-PRO according to applicable legal and ethical requirements
* Indication for proton therapy
* ≥ 18 years old
* ECOG PS (performance status scale) 0-2

Exclusion Criteria:

* Age \< 18 years old
* ECOG (performance status scale) \>3
* Life expectancy \< 3 months
* Inability to provide informed consent

Where it's running

• IRCCS Humanitas Research Hospital
  Rozzano, Michigan, Italy Recruiting

Study contacts

• Study coordinator: Marta Scorsetti, MD, radiation oncologist
• Email: marta.scorsetti@hunimed.eu
• Phone: +39 0282248524

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Protoacoustic Imaging to See Radiation Delivery in Proton Therapy

  This study tests radioacoustic imaging with ultrasound to help doctors see where proton therapy is delivering radiation for liver and prostate cancer patients.

  Recruiting University of Oklahoma · Oklahoma City, Oklahoma · NCT07832617

• Proton Therapy Treatment-Planning Software: Checking How Well RayStation and RayCare Work in Real Care

  This study tests whether the RayStation 2025 and RayCare 2025 software upgrades reliably support delivering standard proton therapy to adults.

  Recruiting University of Wisconsin, Madison · Madison, Wisconsin · NCT07759999

• Proton total marrow irradiation before allogeneic transplant for high-risk AML or MDS

  This trial tests whether adding proton-based total marrow irradiation to standard chemotherapy conditioning before allogeneic stem cell transplant can improve outcomes for adults with high-risk or relapsed/refractory AML or MDS.

  Recruiting at 2 sites Phase 1/2 Institute of Hematology and Blood Transfusion, Czech Republic · Prague and 1 other locations · NCT07532824

• Ultra‑ vs moderately hypofractionated proton therapy after lumpectomy for early breast cancer

  This compares a very short (5-session) proton radiation schedule to a moderate (15-session) proton schedule for women 40 and older after lumpectomy for early-stage breast cancer.

  Recruiting Shanghai Proton and Heavy Ion Center · Shanghai · NCT07135661

• Comparing two types of radiation therapy for breast cancer

  This study is testing whether a new type of radiation therapy for breast cancer is safer and more effective than the standard treatment to help patients feel better and live longer.

  Recruiting Ruijin Hospital · Shanghai, Shanghai Municipality · NCT06826885

• Proton therapy for advanced cervical cancer

  This study is testing whether combining proton therapy with standard chemotherapy and brachytherapy can help people with advanced cervical cancer while reducing side effects.

  Recruiting Phase 2 University of Aarhus · Copenhagen · NCT06462378

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.